featured
Semaglutide Reduces CV Events in Type 2 Diabetes Across the Spectrum of CV Risk
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Semaglutide (SUSTAIN and PIONEER) Reduces Cardiovascular Events in Type 2 Diabetes Across Varying Cardiovascular Risk
Diabetes Obes Metab 2020 Jan 05;[EPub Ahead of Print], M Husain, SC Bain, OK Jeppesen, I Lingvay, R Sørrig, MB Treppendahl, T VilsbøllFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.